Medtronic plc. ($MDT) Stock Forecast: Down 2.8% Today

What is Medtronic plc.?

Medtronic PLC ($MDT) is a global healthcare company that focuses on medical technology, services, and solutions. The company is recognized for its innovations in structural heart and aortic products, continuous glucose monitoring devices, and interventional cardiology.

Why is Medtronic plc. going down?

MDT stock is down 2.8% on Feb 4, 2026 16:56

• The retirement announcement of Medtronic's Senior Vice President and President of Structural Heart and Aortic, Nina Goodheart, has led to uncertainty among investors regarding future leadership and strategic direction in that segment, resulting in a bearish movement in the stock.
• Despite Medtronic's acquisition plans for CathWorks and the positive news of institutional investors increasing their stakes in the company, the market reaction may be linked to concerns about the potential impact of leadership changes on key product lines.
• The projected growth potential in the continuous glucose monitoring devices market, with a estimated market size of US$10.72 billion by 2033, might be overshadowed by worries about the immediate leadership transition within Medtronic's structural heart division.
• The current bearish movement in Medtronic's stock may stem from a combination of profit-taking following recent positive developments and investor caution regarding upcoming changes in crucial leadership positions within the company.

MDT Price Chart

MDT Technical Analysis

MDT News

Medtronic Structural Heart President Nina Goodheart to retire

Medtronic's Senior Vice President and President of Structural Heart and Aortic, Nina Goodheart, has announced her retirement after nearly two decades with the company. Goodheart, who oversaw significant advancements in technologies like the Evolut TAVR platform and Harmony TPV system, expressed profound gratitude for her time at Medtronic. She plans to retire this month, leaving the organization in a strong position.

https://www.massdevice.com/medtronic-structural-heart-president-nina-goodheart-retire/

Continuous Glucose Monitoring Devices Market to Reach US$10.72 Billion by 2033 | CAGR 8.1% | North America Leads with 42% Share | Key Players: Abbott, Dexcom, Medtronic

The global continuous glucose monitoring (CGM) devices market is projected to reach US$10.72 billion by 2033, growing at an 8.1% CAGR, up from US$5.24 billion in 2023. This growth is driven by the increasing prevalence of diabetes, technological advancements like enhanced sensor accuracy and digital health integration, and expanding use in non-insulin and pre-diabetic populations. North America currently leads the market with a 42% share, while Asia-Pacific is the fastest-growing region.

https://www.openpr.com/news/4377508/continuous-glucose-monitoring-devices-market-to-reach-us-10-72

Medtronic set to acquire CathWorks for $585m

Medtronic plans to acquire medical device company CathWorks for $585 million, exercising an option following a 2022 partnership. CathWorks specializes in diagnosing and treating coronary artery disease using its AI-powered FFRangio System. The acquisition is subject to regulatory approvals and is expected to close by the end of Medtronic's FY26.

https://www.medicaldevice-network.com/news/medtronic-to-acquire-cathworks-585m/

Equity Investment Corp Grows Stock Holdings in Medtronic PLC $MDT

Equity Investment Corp increased its stake in Medtronic PLC by 1.4% in the third quarter, making it their fifth-largest holding. Medtronic reported stronger-than-expected quarterly earnings and revenue, and institutional investors now own 82.06% of the company's stock. Medtronic also plans to acquire CathWorks to enhance its heart-imaging capabilities, and analysts generally rate the stock as a "Moderate Buy."

https://www.marketbeat.com/instant-alerts/filing-equity-investment-corp-grows-stock-holdings-in-medtronic-plc-mdt-2026-02-04/

Envestnet Asset Management Inc. Raises Stock Position in Medtronic PLC $MDT

Envestnet Asset Management Inc. increased its stake in Medtronic PLC by 5.0% in Q3, now owning 5,694,827 shares valued at $542.4 million. This move comes as Medtronic plans to acquire CathWorks for up to $585 million, enhancing its interventional cardiology portfolio, and after the company reported strong Q3 earnings, beating estimates with $1.36 EPS and $8.96B revenue. Medtronic also announced a quarterly dividend of $0.71 per share.

https://www.marketbeat.com/instant-alerts/filing-envestnet-asset-management-inc-raises-stock-position-in-medtronic-plc-mdt-2026-02-04/

Trending Today

Ethereum ($ETH) Crypto Forecast: Down 5.5% Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.3% Today

Medtronic plc. Price History

04.03.2025 - MDT Stock was down 5.5%

• MDT's stock (MDT) saw a -1.09% decrease, signifying a bearish trend.
• The decline in MDT's stock price may be linked to investors taking profits following a recent uptick.
• Concerns over potential regulatory changes in the healthcare sector could be making investors cautious, resulting in the drop in MDT's stock.
• This bearish movement in MDT's stock is likely a brief correction in response to market conditions rather than an indication of the company's underlying performance.

04.01.2026 - MDT Stock was down 2.8%

• The retirement announcement of Medtronic's Senior Vice President and President of Structural Heart and Aortic, Nina Goodheart, has led to uncertainty among investors regarding future leadership and strategic direction in that segment, resulting in a bearish movement in the stock.
• Despite Medtronic's acquisition plans for CathWorks and the positive news of institutional investors increasing their stakes in the company, the market reaction may be linked to concerns about the potential impact of leadership changes on key product lines.
• The projected growth potential in the continuous glucose monitoring devices market, with a estimated market size of US$10.72 billion by 2033, might be overshadowed by worries about the immediate leadership transition within Medtronic's structural heart division.
• The current bearish movement in Medtronic's stock may stem from a combination of profit-taking following recent positive developments and investor caution regarding upcoming changes in crucial leadership positions within the company.

14.00.2025 - MDT Stock was up 5.2%

• Medtronic experienced a bullish movement, potentially influenced by positive analyst coverage and forecasts for Anteris Technologies, a player in the transcatheter valve replacement market.
• Analysts' positive outlook on Anteris Technologies' DurAVR valve system, expected to gain a significant market share by 2030, likely bolstered investor confidence in the broader medical technology sector.
• The encouragement of innovative technologies in healthcare may have positively impacted Medtronic, leading to an increase in its stock price.
• The optimistic view on advancements in transcatheter valve replacement technologies could be a contributing factor to Medtronic's overall bullish stock performance.

05.00.2026 - MDT Stock was up 0.7%

• Medtronic PLC (MDT) experienced a strong bullish movement today.
• The company exceeded Q3 earnings estimates, reporting $1.36 EPS and $8.96 billion in revenue, and provided a positive forecast for FY26 EPS.
• The market movement could be attributed to a firm lowering its stake in MDT by 9.9% in Q3, potentially signaling confidence in the company's future performance.
• The overall positive sentiment towards AI-powered medical stocks, including MDT, as highlighted in discussions focusing on the integration of AI in the medical sector, could have also contributed to the bullish movement.

20.07.2025 - MDT Stock was up 5.3%

• Medtronic is a multinational medical technology company headquartered in Ireland, known for developing and manufacturing medical devices and equipment.
• The company reported strong Q1 earnings and revenue beats, along with an increased full-year EPS outlook, despite a slight decline in stock price.
• Q1 sales, adjusted EPS, and FY26 sales guidance all surpassed estimates.
• Analysts revised their forecasts ahead of the earnings call, expecting positive results for the company.
• The stock's positive movement today reflects the impact of the encouraging earnings report and raised sales guidance, even amid a minor drop in stock price.

23.09.2025 - MDT Stock was down 3.2%

• Medtronic (MDT) experienced a bearish movement today.
• The market might have reacted negatively due to potential concerns about the company's financial performance or future growth prospects.
• The news about businesses using Giftbit for rewards may not have directly impacted Medtronic's stock price, leading investors to focus on other factors affecting the company.
• Investors may be reevaluating their positions in Medtronic based on broader market trends or specific industry developments.

18.10.2025 - MDT Stock was up 5.1%

• Following its Q2 earnings, Medtronic (MDT) saw a strong upward trend in its stock value, buoyed by exceeding earnings expectations and showcasing robust growth in the Cardiovascular segment.
• The company's revised 2026 outlook also bolstered investors' confidence, leading to a rise in the stock price.
• Analysts' positive forecast adjustments prior to the earnings announcement foreshadowed a strong performance, paving the way for the stock's climb post-earnings.
• Market response indicates investor trust in Medtronic's financial stability and growth opportunities, driving the stock's ascent as optimism for future success grows.

18.10.2025 - MDT Stock was up 6.0%

• Medtronic (MDT) surpassed earnings and revenue forecasts for the second quarter, demonstrating strong financial results.
• Analysts raised their projections before the earnings announcement, indicating confidence in the company's expansion opportunities.
• The optimistic projections for Medtronic's Cardiovascular unit and Diabetes segment potentially influenced the stock's upward movement, highlighting potential growth in these key sectors.
• Overall, investors reacted favorably to Medtronic's robust performance and promising future prospects, leading the stock to climb higher.

21.04.2025 - MDT Stock was down 2.5%

• The stock declined despite surpassing Q4 forecasts and revealing plans to spin off its Diabetes business.
• The market's reaction could be attributed to profit-taking following recent positive developments, leading to a temporary downward trend.
• Investors may be exercising caution concerning the potential implications of the spinoff on Medtronic's operational efficiency and future growth opportunities.
• The stock's drop might also be influenced by broader market conditions or sector-specific factors impacting investor sentiment towards healthcare companies.

17.06.2024 - MDT Stock was up 3.6%

• Forecasts suggest a promising future for the Medical Technology Platform Market, with frontrunners like Medtronic driving innovation. This optimistic projection likely influenced the bullish trend in MDT stock.
• Medtronic's outperformance in market returns reflects investors' trust in the company's capabilities and growth prospects, boosting its stock value.
• The award bestowed upon Medtronic for its commitment to disability inclusion underscores its dedication to diversity and advancement, resonating positively with investors and buoying the stock price.
• In a quest for high-yield dividend opportunities to offset inflation, Medtronic's reliability and growth potential have piqued investors' interest, further fueling the bullish momentum in the stock.

22.04.2025 - MDT Stock was down 5.8%

• Despite delivering strong fourth-quarter fiscal 2025 results with improvements in margins, Medtronic's stock experienced a bearish movement.
• The decision to spin off its Diabetes business into a standalone company could have initially raised concerns among investors about the potential impact on overall performance.
• The beat in Q4 earnings and revenue estimates might not have been substantial enough to offset broader market sentiment or concerns about the upcoming restructuring.
• Investor optimism about Medtronic's strength in the Cardiovascular portfolio may have been overshadowed by uncertainties surrounding the strategic shift in the company's business structure.

01.09.2025 - MDT Stock was down 2.3%

• Medtronic's stock price saw a 1.5% decrease amidst overall market pessimism.
• The larger decline in Medtronic's stock compared to the market suggests company-specific influences.
• Potential factors contributing to the bearish trend may involve earnings discrepancies, regulatory hurdles, or adverse developments impacting investor trust in the company's outlook.